Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azathioprine, mycophenolate mofetil, rituximab and IVIg for relapse prevention in pediatric MOG antibody-associated disease
ChiCTR2100048742Phase 4Recruiting
- Sponsor
- Peking University First Hospital
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of azathioprine, mycophenolate mofetil, rituximab and immune globulin in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) (4 arms), sponsored by Peking University First Hospital. Primary endpoint: 2-year relapse rate. Started Aug 2021; status: recruiting.
02
Drugs
azathioprinemycophenolate mofetilrituximabimmune globulin
03
Conditions
myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)
Beyond the preview
Go deeper on ChiCTR2100048742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048742.